t; > peter.bon...@astellas.com <mailto:peter.bon...@astellas.com>
> >
> > (224) 619-4901
> >
> > Quote of the week –
> >
> > /“Dancing with the Stars” is not owned by Astellas.**/
> >
> > *From:* owner-nmus...@globomaxnm.com *On
> > B
:* Re: [NMusers] flip-flop without absorption information?
This is an interesting discussion. At the same time I can't get my head
around the assumption of any covariate on a flip-flop phenomenon. In
other words, even if there is no information on covariates
this phenomenon could still exis
gt;
> Quote of the week –
>
> *“Dancing with the Stars” is not owned by Astellas.*
>
>
>
> *From:* owner-nmus...@globomaxnm.com *On
> Behalf Of *Shan Pan
> *Sent:* Tuesday, September 13, 2022 3:42 AM
> *To:* Jakob Ribbing ; Niurys.CS <
> amaranth...@gmail.com&g
owner-nmus...@globomaxnm.com On Behalf Of
Shan Pan
Sent: Tuesday, September 13, 2022 3:42 AM
To: Jakob Ribbing ; Niurys.CS
Cc: nmusers
Subject: Re: [NMusers] flip-flop without absorption information?
This is an interesting discussion. At the same time I can't get my head around
the a
...@globomaxnm.com Namens Jakob
Ribbing
Verzonden: dinsdag 13 september 2022 06:23
Aan: Niurys.CS ; nmusers
Onderwerp: Re: [NMusers] flip-flop without absorption information?
Dear Niurys,
It would be down to distributional assumptions in that case.
For example if you have a very strong predictor (covariate
Hi Niurys,
Depending on the size of your peptide and the timing of the first
observations, it might also be likely that the rate limiting step for the
terminal elimination phase is the (re)distribution from the peripheral to
the central compartment, rather than the absorption.
This is nicely demon
This is an interesting discussion. At the same time I can't get my head
around the assumption of any covariate on a flip-flop phenomenon. In other
words, even if there is no information on covariates this phenomenon could
still exist.
It's my understanding that this flip-flop phenomenon is fundame
Dear Niurys,
It would be down to distributional assumptions in that case.
For example if you have a very strong predictor (covariate) of either
elimination or absorption rate (but not both) - data could be informative to
discriminate between flip-flop or not.
Had your therapeutic been IgG monoc
Dear nmusers,
I'm working on the population PK of a therapeutic peptide candidate for
rheumatoid arthritis. Three dose levels of the peptide were administered as
a single subcutaneous injection.
We have some limitations, for instance, the dataset is very sparse and is
lacking in the information of
